Patients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said. Patient information leaflets for Wegovy, Ozempic and Mounjaro list pancreatitis as an “uncommon” reaction, affecting about one in 100 patients. Acute pancreatitis occurs when the pancreas, a gland located behind the stomach that aids in digestion, becomes suddenly inflamed. To date, there have been 146 reports of acute and chronic pancreatitis from those taking liraglutide and 61 from those taking dulaglutide. We take reports regarding patient safety seriously and actively monitor, evaluate, and report safety information for all our medicines.